• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

Cordis Corp.

FDA says Cordis carotid artery stent recall is serious

April 23, 2021 By Sean Whooley

The FDA has classified Cordis‘ recall of its Precise Pro Rx carotid system as Class I, the most serious kind of recall. Cordis in February recalled certain lots of its Precise Pro RX carotid stent systems because of a risk of separation of the atraumatic distal tip of the sheathed delivery system in patients. The […]

Filed Under: Cardiovascular, Catheters, Featured, Food & Drug Administration (FDA), Recalls, Regulatory/Compliance, Stents, Vascular Tagged With: Cordis, Cordis Corp., FDA

Silk Road Medical issues voluntary recall of Enroute transcarotid stent system

January 25, 2021 By Sean Whooley

Silk Road Medical (NSDQ:SILK) announced today that it is voluntarily recalling additional lots of its Enroute transcarotid stent system. Enroute, which is manufactured by Cardinal Health (NYSE:CAH) subsidiary Cordis, has received a total of six product complaints between September 2020 and January 2021 involving an issue in which a tip detaches from the stent delivery system. Additionally, test […]

Filed Under: Blood Management, Featured, Food & Drug Administration (FDA), Recalls, Regulatory/Compliance, Vascular Tagged With: Cardinal Health, Cordis Corp., Silk Road Medical Inc.

Cardinal Health’s Cordis expands recall of some Powerflex Pro catheters

August 28, 2019 By Brad Perriello

Cardinal Health (NYSE:CAH) subsidiary Cordis this week expanded the recall of some of its Powerflex Pro catheters for treating peripheral artery disease, adding three lots to the list. Santa Clara, Calif.-based Cordis first recalled five lots of the Powerflex Pro device in Sept. 6, 2018, after a supplier said they didn’t meet an internal specification for […]

Filed Under: Catheters, Featured, Recalls Tagged With: Cardinal Health, Cordis Corp., Peripheral

Cardinal Health beats The Street on Q2 & FY 2019 earnings, expects $145 million restructuring charge

August 8, 2019 By Nancy Crotti

Cardinal Health (NYSE:CAH) beat Wall Street’s earnings consensus by 10% for the fourth quarter of 2019, despite a disappointing performance by its medical sector. The Dublin, Ohio-based company posted profits of $194 million or $0.65 per share on sales of $37.4 billion for the three months ended June 30, 2019, for a bottom-line gain of […]

Filed Under: Blog, Business/Financial News, Featured, News Well, Wall Street Beat Tagged With: Cardinal Health, Cordis Corp.

Cardinal Health’s Cordis launches Mynx Control vascular closure system

November 5, 2018 By Fink Densford

Cardinal Health (NYSE:CAH) subsidiary Cordis said last Friday that it launched the Mynx Control vascular closure device intended for sealing 5-7 French femoral arterial access sites. The newly launched system is intended to reduce time to hemostasis and ambulation after diagnostic or interventional procedures, the Dublin, Ohio-based company said. The system also includes a next-generation deployment system designed to […]

Filed Under: Business/Financial News, Featured, Vascular Tagged With: Cardinal Health, Cordis Corp.

Aegea Medical picks up former Cardiokinetix, Concentric Medical CEO Sainz | Personnel Moves – May 14, 2018

May 14, 2018 By Fink Densford

Aegea Medical said last week it tapped former Cardiokinetix prez & CEO Maria Sainz as its new president and chief executive officer, effective immediately. Sainz will replace former CEO Don Gurskis, who has held the corner office since 2013. Gurskis will remain on as member of the Redwood City, Calif.-based company’s executive management team. “Maria is […]

Filed Under: Business/Financial News Tagged With: ACell, aegeamedical, Boston Scientific, Cardiac Dimensions Inc., CardioKinetix Inc., cellectbiotechnology, Cerus Corp., Concentric Medical Inc., Conventus Orthopaedics, Cordis Corp., Covidien, GE Healthcare, Guidant Corp., Hillrom, InfraReDx Inc., Nellix Inc., Nipro, Personnel Moves, sciton, Sensus Healthcare LLC, Stryker, Viveve Medical

Cardinal Health’s Cordis wins date with FDA panel for Incraft AAA stent graft

May 10, 2018 By Fink Densford

Cardinal Health (NYSE:CAH) subsidiary Cordis this week won a June date with an FDA panel looking to discuss the premarket approval application for its InCraft AAA stent graft system designed for treating infrarenal abdominal aortic aneurysms. On June 12, the FDA’s Medical Device Advisory Committee’s Circulatory Systems Devices Panel will meet to discuss possible marketing applications for […]

Filed Under: Food & Drug Administration (FDA), Regulatory/Compliance, Stent Grafts, Vascular Tagged With: Cardinal Health, Cordis Corp.

US Court of Appeals revives Medinol stent suit against Cordis

April 23, 2018 By Fink Densford

The US Court of Appeals for the Federal Circuit this week revived a stent patent infringement suit brought by Medinol against Cordis and its former parent company Johnson & Johnson (NYSE:JNJ). The suit, originally filed in 2013, claimed that Cordis infringed on Medinol stent patents filed between 1999 and 2005. The case was vacated in 2014 […]

Filed Under: Legal News, Patent Infringement, Stents Tagged With: Cordis Corp., Medinol Ltd

Cordis, Medinol tout first commercial implants of Elunir drug-eluting stent in U.S.

January 11, 2018 By Sarah Faulkner

Cordis and Medinol announced today that the first commercial uses of the Elunir drug-eluting stent in the U.S. were performed at New York-Presbyterian Hospital/Columbia University Medical Center and the Piedmont Heart Institute in Atlanta. The Elunir stent, developed by Medinol and distributed by Cordis, features a metallic spring tip and the narrowest strut width of any stent on […]

Filed Under: Drug-Device Combinations, Drug-Eluting Stents, Implants, Pharmaceutical, Wall Street Beat Tagged With: Cordis Corp., Medinol Ltd

Cordis, Medinol win FDA nod for Elunir drug-eluting stent

November 30, 2017 By Sarah Faulkner

Cordis and Medinol announced today that the FDA approved its Elunir drug-eluting stent for the treatment of patients with narrowing or blocked coronary arteries. The stent, designed by Medinol and distributed exclusively by Cordis in the U.S., features a novel metallic spring tip and the narrowest strut width of any stent on the market in the U.S., according […]

Filed Under: Drug-Device Combinations, Drug-Eluting Stents, Food & Drug Administration (FDA), Pharmaceutical, Regulatory/Compliance, Vascular Tagged With: Cordis Corp., Medinol Ltd

Cordis inks exclusive distribution deal for Medinol’s coronary stent portfolio in US

October 30, 2017 By Sarah Faulkner

Cordis has inked an exclusive distribution deal to sell Medinol‘s coronary stents in the U.S., the company reported, adding a cobalt-chromium bare-metal stent and a drug-eluting stent to its portfolio. According to the deal, Cordis plans to start selling Medinol’s NIRxcell BMS immediately and will exclusively distribute the company’s EluNir drug-eluting stent if it wins FDA approval. […]

Filed Under: Cardiovascular, Drug-Device Combinations, Drug-Eluting Stents, Pharmaceutical, Stents, Vascular Tagged With: Cordis Corp., Medinol Ltd

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 13
  • Go to Next Page »

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy